Summary ,B-NGF is a determinant of sympathetic innervation and a neural differentiation factor. In RT-PCR where a 542 bp product was found with specific primers for the human f,-NGF cDNA sequence.
Beta nerve growth factor (f,-NGF) stimulates the growth of sympathetic and some sensory neurites; in vitro, NGF was found to stimulate the growth of dendritic processes from the undifferentiated PC-12 rat adrenal phaeochromocytoma cellline (Tischler and Greene, 1975) while, in vivo, in adult mammals, tissue NGF concentrations correlated with the density of tissue sympathetic innervation (Korsching and Thoenen, 1983) . NGF also acts as a positive chemotaxin for neurones and may facilitate their contact with their target tissues (Gundersen and Barrett, 1980) . NGF production, therefore, is a means whereby tissues influence the density and distribution of their sympathetic and sensory innervation.
Mouse /3-NGF is a homodimer of two protein molecules of 14.5 kDa each. f,-NGF purified from mouse salivary glands (the most abundant source of the hormone) is shortened during purification to a 26.5 kDa dimer known as 2.5S mNGF (Bradshaw, 1978) . Mouse and human f-NGF show 92% sequence homology and are immunologically similar, such that antibodies raised against the mouse protein will recognise the human (Nikolics, 1993; Naher-Noe et al., 1993) . The mouse f3-NGF gene is expressed as a number of splice variants (Nikolics, 1993) . However, only one transcript of the highly homologous (Ullrich et al., 1983) human gene has so far been described; this mRNA transcript is spliced from just two exons. The whole sequence of the mature hormone is coded in one exon (Borsani et al., 1990) . ,B-NGF dimers are non-covalently bound, and the hormone appears as a monomeric form under denaturing conditions. Study of f,-NGF in neoplasia has emphasised its possible role in tumours derived from the neural crest and in neurogenic tumours. In the D54 glioma, U1 18 and U251 glioblastomas, TE671 medulloblastoma and Hs294 melanoma cell lines, /B-NGF treatment leads to variable differentiation of these cells with a reduction in growth rates (Yaeger et al., 1991) . All of these cell lines bear /3-NGF receptors, with melanoma cell lines having a particularly high concentration of these receptors (Buxser et al., 1984) . The capacity of ,B-NGF to inhibit growth of neurogenic tumours is supported by the in vivo finding that neuroblastomas which express high-affinity f,-NGF receptors have a better prognosis than those which do not (Kogner et al., 1993) .
In spite of the role of adrenergic innervation in outflow tract obstruction (Lepor and Shapiro, 1990) and recent interest in prostate neuroendocrine cells as a prognosticator in prostate adenocarcinomas (Cohen et al., 1991) , ,B-NGF has received little attention in the human prostate. In the prostates of rodents, it may be present in high concentration and is localised to prostate epithelium (Harper and Thoenen, 1980; Shikata et al., 1984; MacGrogan et al., 1990) . Recently, MacGrogan et al. have found f,-NGF expression and variable ,B-NGF concentrations (0-1720 pg g-') in human benign hyperplastic (BPH) tissue (MacGrogan et al., 1992) .
Furthermore, Djakiew's group have localised f,-NGF to the stroma of the human gland by immunohistochemistry (Graham et al., 1992 ) -a surprising result in view of the high degree of conservation of the hormone and its epithelial localisation in other mammals. In cell culture studies, this group have demonstrated that proteins produced by prostate stromal and epithelial cells that are immunologically related to, but heavier than, /3-NGF (42-65 kDa), stimulate the growth of both stromal and epithelial cells in culture (Djakiew et al., 1991) .
The aims of this study were to examine the expression of fl-NGF in benign hyperplastic and malignant human prostate tissue at the protein and mRNA levels. f3-NGF concentration and neuroendocrine cell content of prostate adenocarcinomas were also compared. Chomczynski and Sacchi (1987) . Briefly, 5 jig of sample RNA were reverse transcribed by the addition of 20 jil of 25 mm magnesium chloride, 10 Mil of transcriptase buffer, 10 jil of 10 mM dNTP mixture, 100 U RNAsin, 2.5 jil of oligo (dT) and 67.5 U AMV reverse transcriptase ('Reverse transcription system' kit, Promega Corporation, Southampton, UK). The mixture was incubated for 1 h at 42°C. f,-NGF primer sequences were 5'-GACCCAAGCT-CAGCTCAGC-3' and 3'-TATTCTGGTGGCGGTGTCTG-5', defining a 542 bp fragment designed from the human /3-NGF cDNA sequence (Borsani et al., 1990 Aliquots of 300 jig of prostate protein and 5, 10 and 50 ng rh,B-NGF standards along with 20 ,ul of 'Rainbow' molecular weight markers (Amersham International, Amersham, UK), were electrophoresed at 20 mA in the stacking gel (5% polyacrylamide, 187.5 mM Tris, 0.1% SDS, 0.1% ammonium sulphate) and 40 mA in the resolving gel (15% polyacrylamide, 375 mM Tris, 0.1% SDS, 0.1% ammonium sulphate), using Tris-glycine as a running buffer (25 mM tris-HCl, 575 mM glycerine, 0.1% (w/v) SDS). The gels were equilibrated in transfer buffer [48 mM tris base, 39 mM glycine, 20% (v/v) methanol and 0.0375% (w/v) SDS] and blotted overnight onto nitrocellulose membranes ('Hybond-C', Amersham International) using a Biorad 'Trans-blot' semi-dry apparatus. The membranes were washed in TNF (50 mM tris base, 150 mm sodium chloride, 2 mM EDTA) and blocked in the same solution with 2% (w/v) BSA and 5% (w/v) semi-skimmed dried milk for 2 h at room temperature. The membranes were then incubated for 1 h in the blocking solution with 1:1000 polyvalent rabbit anti-2.5S mNGF. Bound primary antibody was detected by incubation in the blocking solution with 1:1000 horseradish peroxidase-conjugated whole donkey anti-rabbit IgG for 1 h at room temperature. Antibody detection was performed with the enhanced chemoluminescence (ECL), Western blotting analysis system (Amersham).
Materials and methods

Tissues
Immunohistochemical staining for f,-NGF and neuroendocrine cells Frozen sections of prostate tissue and adrenal gland (7-8 jim) were cut, fixed in methanol (4°C, 3 min) and stained for f,-NGF. The ,B-NGF primary antibody was polyvalent rabbit anti-2.5S mNGF (Universal Biologicals, London, UK) diluted 1:100 in Tri-buffered saline (TBS) with 3.5% bovine serum albumin (BSA) and 0.1% sodium azide (TBS/BSA/ azide). For neuroendocrine cell staining 4 gm sections of the paraffin-embedded malignant prostate and autopsy pancreas tissues were used. The primary antibody was polyvalent rabbit anti-human PGP9.5 (Ultraclone, Isle of Wight, UK; 1: 400 in TBS/BSA/azide).
Briefly, slides were incubated in 20% normal sheep serum (Scottish Antibody Production Unit, Carluke, UK) in TBS for 30 min before exposure to the primary antibody for 30 min. After a TBS wash, sections were subsequently incubated with a secondary sheep anti-rabbit IgG biotinylated F(ab')2 fragment (Boehringer Mannheim Biochemica, Lewes, UK), at a dilution of 1: 400 in TBS/BSA/azide for 30 min. After a further TBS wash, slides were incubated with streptavidin-linked alkaline phosphatase ('extravidin', Sigma, 1: 1000 in TBS/BSA/azide) for 30 min. The substrate colour reaction was developed with fuchsin chromogen solution ('New Fuchsin', Dako, High Wycombe, UK) for 15 min before counterstaining with Mayer's haematoxylin for 1 min. Slides were air-dried and mounted with DPX medium and cover-slips. The adrenal and pancreatic tissues provided positive controls for f3-NGF and PGP9.5 staining, respectively, while negative controls were carried out with the omission of the primary antisera from the TBS/BSA/azide preparation.
Sections were examined for positive staining for ,B-NGF and PGP9.5 by an independent pathologist. Tumours were simply classified as positive or negative for PGF9.5.
Enzyme-linked immunosorbent assay (ELISA)
The concentration off,-NGF in prostate tissues from patients with BPH and prostate cancer was measured as follows: 230 -550 mg of frozen prostate tissue was pulverised in a 'mikrodismembrator', (Braun Medical, Aylesbury, UK) and the powdered tissue was suspended in 500 jil of 100 mM tris-HCI containing 400 mm sodium chloride, 2% (w/v) BSA, 0.1% (w/v) sodium azide, 4 mM EDTA, 1 mM phenylmethylsulphonyl fluoride (PMSF) and 7 ug ml-' aprotinin and homogenised with an 'Ystrall' homogeniser (Ystrall GmbH, Dottingen, Germany Figure 9 ).
The relationship between f,-NGF concentrations and PGP9.5 staining in prostate cancer
The P-NGF concentrations in prostate cancer were correlated to the PGP9.5 staining patterns but there was no difference found between PGP9.5 positive (n= 7; mean ,B-NGF concentration 3238 pg g-') and the PGP9.5 negative (n = 8; mean ,B-NGF concentration 2982 pg g-') groups (P=0.773). Similarly, after correction for morphometric data, there was no significant difference between the two groups (PGP9.5 positive, mean = 1141 pg 100 mg 1; PGP9.5 negative, mean= 959 pg 100 mg-', P =0.452).
Discussion
The data presented in this study demonstrated the immunohistochemical localisation of JJ-NGF to the epithelial elements in prostate tissue. This contrasts to earlier studies showing that fJ-NGF localised to the prostate stroma. While both studies employed the same primary fl-NGF antiserum, there were differences in the techniques employed with regard to blocking agents. The earlier report by Graham et al. (1993) used ovalbumin with a goat secondary antibody, whereas, in the present study, we employed 20% sheep serum along with a sheep secondary antibody. Whether this would account for the differences seen is not clear, but it is well established that the use of blocking and secondary sera from the same species produces less non-specific staining (Bancroft and Cook, 1994 (Harper and Thoenen, 1980; Shikata et al., 1984; MacGrogan et al., 1990 (Allen et al., 1995) . Although the presence of these cells may not be a prognosticator, there is evidence that as prostate adenocarcinomas dedifferentiate (Allen et al., 1995) , progress (Aprikian et al., 1994) and become androgen independent (Berner et al., 1993) , they contain a higher portion of neuroendocrine elements. It is also clear that these cells do not bear androgen receptors in normal hyperplastic or adenocarcinomatous prostate tissues (Iwamura et al., 1994; Bonkhoff et al., 1993) and that some of their secreted products may be growth promoting for prostate epithelial cells (Power et al., 1991; Pinski et al., 1993) . Therefore, it can be postulated that androgen depletion therapies confer a survival advantage to neuroendocrine cells over other prostate cancer cells and that neuroendocrine cells may then promote androgen-independent prostate cancer growth (di Sant-Agnese, 1995) .
Because of local experience in staining bronchogenic carcinomas for neuroendocrine elements with antibodies against PGP9.5, that antibody was used to stain neuroendocrine cells in prostate tissue. As far as we are aware, this is the first report of such a use of this antibody. PGP9.5 is a 25 kDa hydrolase which is specifically associated with neural and neuroendocrine cells (Wilson et al., 1988) and which is responsible in those cells for the C-terminal hydrolysisactivation of ubiquitin (Jentsch, 1992) .
The proportion of adenocarcinomas showing PGP9.5 staining in the present study was 46.7%, and this was similar to the figure found by di Sant-Agnese and Jensen (1987) , using the argyrophil reaction and a battery of immunohistochemical stains (47%). Interestingly, we were unable to detect any correlation between the concentration of the neural differentiation factor f,-NGF and the presence of neural differentiation, as demonstrated by positive PGP9.5 staining.
Western blot analysis of prostate proteins with the primary antiserum used in immunohistochemistry identified a single protein band which co-migrated with a sample of rh,B-NGF. Earlier studies by Djakiew et al. (1991) have also described heavier NGF-like protein products kDa) from prostate cell cultures, but there was no evidence of these heavy NGF-like proteins in the human prostate tissues analysed here. NGF-like proteins in the human prostate represent fl-NGF itself, while heavier NGF-like proteins were not detected in native human tissue.
fl-NGF in peripheral tissues has predominantly been regarded as a determinant of sympathetic and sensory innervation. Recent studies have demonstrated that, in addition, NGF is involved in the paracrine control of prostate epithelial growth through the production of NGF by prostate stroma (Graham et al., 1992) ; these act mitogenically via specific receptors on the epithelium (Djakiew et al., 1991) .
However, our own data do not support this view as we have immunohistochemically localised ,B-NGF to prostate epithelium and confirmed this by demonstrating the presence of a positive correlation between f,-NGF concentration and the epithelial content of prostate tissue. Malignant prostate epithelia contain less ,B-NGF than do benign epithelia, but the concentration of /3-NGF in malignant tissue, as a whole, is higher than that in benign tissue.
The data presented here suggest that fl-NGF is an endogenous product of the prostate gland and f,-NGF concentrations present in the gland (1-6 ng g -') are similar to concentrations causing neuronal differentiation and growth in vivo (Tischler and Greene, 1975 (Tenniswood, 1986) .
